Citation

  • Authors: Liu, Z., Xu, S., Huang, X., Wang, J., Gao, S., Li, H., Zhou, C., Ye, J., Chen, S., Jin, Z. G., Liu, P. Y.
  • Year: 2015
  • Journal: Br J Pharmacol
  • Applications: in vitro / DNA / jetPEI-HUVEC
  • Cell type: HUVEC
    Description: Human umbilical vein endothelial cells

Abstract

BACKGROUND AND PURPOSE: Cryptotanshinone (CTS) is a major bioactive diterpenoid isolated from Danshen, an eminent medicinal herb that is used to treat cardiovascular disorders in Asian medicine. However, it is not known whether CTS can prevent experimental atherosclerosis. The present study was designed to investigate the protective effects of CTS on atherosclerosis and its molecular mechanisms of action. EXPERIMENTAL APPROACH: Apolipoprotein E-deficient (ApoE(-/-)) mice, fed an atherogenic diet, were dosed daily with CTS (15, 45 mg kg(-1) day(-1)) by oral gavage. In vitro studies were carried out in oxidized LDL (oxLDL)-stimulated HUVECs treated with or without CTS. KEY RESULTS: CTS significantly attenuated atherosclerotic plaque formation and enhanced plaque stability in ApoE(-/-) mice by inhibiting the expression of lectin-like oxLDL receptor-1 (LOX-1) and MMP-9, as well as inhibiting reactive oxygen species (ROS) generation and NF-